Neurocrine Biosciences Inc., of San Diego, said NBI-98854, a small-molecule VMAT2 inhibitor, in development for tardive dyskinesia, showed an excellent safety profile and a clinically meaningful reduction in tardive dyskinesia symptoms in up to 12 weeks of continuous dosing in a Phase IIb trial.